

# Sortilin Binding Compounds, Formulations, and Uses Thereof

Published date: April 16, 2019

## Technology description

USF researchers have developed a compound capable of binding to sortilin. Specifically, the compound modulates distinctive sortilinligand interactions that are known to control proprotein convertase subtilisin/kexin type 9 (PCSK9) secretion. By inhibiting PCSK9 secretion, the novel formulation lowers low-density lipoprotein (LDL) cholesterol. Furthermore, this technique can also increase the amount of LDL receptors, subsequently minimizing the associated cardiovascular disease risks.

Researchers at the University of South Florida have developed novel compounds capable of binding to sortilin or related analogs to treat hypercholesteremia, hepatic steatosis, and Alzheimer's disease.

## Application area

Administration of this compound may be used to treat many medical disorders including hypercholesteremia, hepatic steatosis, and Alzheimer's disease.

## Institution

[University of South Florida](#)

## 联系我们



叶先生

电话：021-65679356

手机：13414935137

邮箱：yeyingsheng@zf-ym.com